Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH

ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.

Related Keywords

California ,United States ,San Diego ,American ,Samsung Bioepis ,S Samsung Bioepi ,European Union ,European Medicines Agency ,Alexion Pharmaceuticals ,American Society Of Hematology Annual Meeting Exposition ,Amgen ,American Society Of Hematology ,Biosimilars Initiative ,Annual Meeting ,Design Cells ,Hematology Annual Meeting ,American Journal ,Reviewed April ,European Medicines ,Updated July ,Biosimilars ,Paroxysmal Nocturnal Hemoglobinuria ,Rare Blood Disorder ,Eculizumab ,